+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Anthracycline-free therapy for HER2-amplified breast cancer



Anthracycline-free therapy for HER2-amplified breast cancer



Lancet. Oncology 14(11): 1037-1038




Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 051563301

Download citation: RISBibTeXText

PMID: 24007747

DOI: 10.1016/S1470-2045(13)70410-8


Related references

Anthracycline-free neoadjuvant therapy induces pathological complete responses by exploiting immune proficiency in HER2+ breast cancer patients. Bmc Cancer 14: 954-954, 2015

Toxicity of dual HER2-blockade with pertuzumab added to anthracycline versus non-anthracycline containing chemotherapy as neoadjuvant treatment in HER2-positive breast cancer: The TRAIN-2 study. Breast 29: 153-159, 2017

Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Annals of Oncology 24(9): 2278-2284, 2014

NK cell-mediated antibody-dependent cellular cytotoxicity is enhanced by tamoxifen in HER2/neu non-amplified, but not HER2/neu-amplified, breast cancer cells. Cancer Immunology, ImmunoTherapy 65(11): 1325-1335, 2016

Detection and Characterization of an Avipoxvirus in a Common Buzzard ( Buteo buteo) in Italy Using a Multiple Gene Approach. Journal of Wildlife Diseases: -, 2018

In a cohort of breast cancer screened patients the proportion of HER2 positive cases is lower than that earlier reported and pathological characteristics differ between HER2 3+ and HER2 2+/Her2 amplified cases. Virchows Archiv 469(1): 45-50, 2016

Long-term follow-up of HER2-overexpressing stage II or III breast cancer treated by anthracycline-free neoadjuvant chemotherapy. Annals of Oncology 22(2): 321-328, 2011

Dual human epidermal growth factor receptor 2 (HER2) blockade and hormonal therapy for the treatment of primary HER2-positive breast cancer: one more step toward chemotherapy-free therapy. Journal of Clinical Oncology 31(14): 1703-1706, 2013

Primary systemic therapy in HER2-amplified breast cancer: a clinical review. Expert Review of Anticancer Therapy 12(8): 1005-1013, 2013

Efficacy of neoadjuvant therapy with trastuzumab concurrent with anthracycline- and nonanthracycline-based regimens for HER2-positive breast cancer. Cancer 118(9): 2385-2393, 2012

A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. Cancer Research 68(14): 5878-5887, 2008

Combined targeting of HER2 and VEGFR2 for effective treatment of HER2-amplified breast cancer brain metastases. Proceedings of the National Academy of Sciences of the United States of America 109(45): E3119-E3127, 2013

Intrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-amplified breast cancer: mechanisms and clinical implications. Critical Reviews in Oncogenesis 17(1): 1-16, 2012

Combination therapy of RY10-4 with the γ-secretase inhibitor DAPT shows promise in treating HER2-amplified breast cancer. Oncotarget 7(4): 4142-4154, 2016

Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines. Annals of Oncology 21(2): 255-262, 2010